Pioneering research by Trained Therapeutix Discovery founders has shown that innate immune responses can be “trained” through epigenetic changes stored in bone marrow progenitor cells. These adaptations, while powerful, can sometimes turn harmful, driving chronic inflammation in conditions like autoinflammatory and cardiovascular diseases. Additionally, recent publications highlight how tumors can remotely reprogram myeloid progenitor cells in the bone marrow, opening new avenues for therapeutic intervention.

Recognizing the potential of these discoveries, Trained Therapeutix Discovery is developing innovative nanomedicines based on apolipoprotein nanoparticles, which were invented by Trained Therapeutix Discovery founders. These nanomedicines are designed to precisely target and reprogram myeloid progenitor cells in the bone marrow, offering a novel approach to innate immunotherapy. By harnessing the adaptability of the innate immune system, Trained Therapeutix Discovery aims to address unmet needs in autoinflammatory diseases and cancer.